SDY8EQ|*<W4&%,>0;#S8XZSI;)PH=5Q~>*RU'/C65QXUNB;
SYSTEM PROCESSING...
SDY8EQ|*<W4&%,>0;#S8XZSI;)PH=5Q~>*RU'/C65QXUNB;
SYSTEM PROCESSING...
Posted: 2025-08-07 12:10:22 UTC
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-08-07 12:10:39 UTC
Verified By
Rollup News
Eli Lilly's weight-loss drug showed disappointing results in trials, causing the company's shares to decline while boosting Novo Nordisk's stock value.
Eli Lilly's stock decline
Boost in Novo Nordisk's stock
Underperformance of Lilly's weight-loss drug in trials
Underperformance of Eli Lilly's weight-loss drug in clinical trials
Negative market reaction to Eli Lilly's drug trial results